The Federal Trade Commission sued the country’s three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.The case accuses UnitedHealth Group’s Optum unit, CVS Health’s CVS Caremark and Cigna’s Express Scripts of unfairly excluding lower cost insulin products from lists of drugs covered by insurers.Driving down drug prices has been a key goal for the Joe Biden admi ...